Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021723 · ClinicalTrials.gov registry record · Phase 2
Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease
A Phase 2 study, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
- Terminated
- Registry status
- Phase 2
- Development phase
- 375
- Enrollment target
NCT00021723: Clinical Trial Phase 2 study, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
NCT00021723 is a Phase 2 study that was terminated before completion, run by JANSSEN Alzheimer Immunotherapy Research & Development. The registered enrollment target is 375 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00021723, a Phase 2 study, was terminated before completion, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 375 participants
- Enrollment target
Study Summary
A multi-center, double-blind, placebo-controlled out-patient, safety, tolerability, and pilot efficacy study of intramuscular AN-1792 in patients with mild to moderate Alzheimer's disease.
Interventions
- BIOLOGICAL AN-1792 also known as AIP-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2001-09 |
| Est. Completion | 2003-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00021723
The ClinicalTrials.gov registry entry for NCT00021723 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 375 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is JANSSEN Alzheimer Immunotherapy Research & Development, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AN-1792 also known as AIP-001 is the first listed.
NCT00021723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00021723 about?
NCT00021723 is a clinical study titled "Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease". A multi-center, double-blind, placebo-controlled out-patient, safety, tolerability, and pilot efficacy study of intramuscular AN-1792 in patients with mild to moderate Alzheimer's disease.
What is the current status of trial NCT00021723?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 375 participants. The study started on 2001-09. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00021723?
The interventions under investigation include: AN-1792 also known as AIP-001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00021723?
This trial is sponsored by JANSSEN Alzheimer Immunotherapy Research & Development, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.